RT Journal Article SR Electronic T1 Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.12.15.20248278 DO 10.1101/2020.12.15.20248278 A1 C Raina MacIntyre A1 Valentina Costantino A1 Mallory Trent YR 2020 UL http://medrxiv.org/content/early/2020/12/19/2020.12.15.20248278.abstract AB Several vaccines for SARS-CoV-2 are expected to be available in Australia in 2021. Initial supply is likely to be limited, and will require a judicious vaccination strategy until supply is unrestricted. If vaccines have efficacy as post-exposure prophylaxis (PEP) in contacts, this provides more policy options. We used a deterministic mathematical model of epidemic response with limited supply (age-targeted or ring vaccination) and mass vaccination for the State of New South Wales (NSW) in Australia. For targeted vaccination, the effectiveness of vaccinating health workers, young people and older adults was compared. For mass vaccination, we tested varying vaccine efficacy (VE) and distribution capacities. With a limited vaccine stockpile of 1 million doses in NSW, if there is efficacy as PEP, the most efficient way to control COVID-19 will be ring vaccination, however at least 90% of contacts per case needs to be traced and vaccinated. Health worker vaccination is required for health system resilience. Age based strategies with restricted doses make minimal impact on the epidemic, but vaccinating older people prevents more deaths. Herd immunity can only be achieved with mass vaccination. With 90% VE, herd immunity can be achieved by vaccinating 66% of the population. A vaccine with less than 70% VE cannot achieve herd immunity and will result in ongoing risk of outbreaks. For mass vaccination, distributing at least 60,000 doses per day is required to achieve control. Slower rates of vaccination will result in the population living with COVID-19 longer, and higher cases and deaths.Competing Interest StatementCR MacIntyre has been on a COVID-19 vaccine advisory board for Seqirus and has consulted on COVID-19 for Astra Zeneca (Australia). She has been on many vaccine advisory boards for other vaccines (influenza, RSV, pneumococcal, zoster) in the past 5 years for Sanofi, Janssen, Seqirus, Merck and Pfizer.Funding StatementThe study was not funded by external funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A - only published data was used in this mathematical modelling study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are from published studies, available in the reference list.